Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Rating of “Hold” from Analysts

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) have received a consensus recommendation of “Hold” from the sixteen ratings firms that are currently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $46.14.

Several research analysts have weighed in on IONS shares. TheStreet upgraded Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Wednesday, July 5th. BMO Capital Markets restated a “buy” rating and issued a $59.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, June 2nd. Needham & Company LLC restated a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a report on Wednesday, May 17th. Leerink Swann restated an “outperform” rating and issued a $45.00 price target (down from $47.00) on shares of Ionis Pharmaceuticals in a report on Wednesday, May 17th. Finally, Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a report on Wednesday, July 12th.

In other news, Chairman Stanley T. Crooke sold 16,500 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $52.10, for a total value of $859,650.00. Following the transaction, the chairman now owns 51,476 shares of the company’s stock, valued at $2,681,899.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP C Frank Bennett sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $59.29, for a total value of $592,900.00. Following the completion of the transaction, the senior vice president now directly owns 25,041 shares in the company, valued at approximately $1,484,680.89. The disclosure for this sale can be found here. In the last three months, insiders have sold 54,379 shares of company stock worth $2,946,052. Company insiders own 1.86% of the company’s stock.

Large investors have recently modified their holdings of the stock. BlackRock Inc. boosted its stake in shares of Ionis Pharmaceuticals by 37,569.7% in the first quarter. BlackRock Inc. now owns 6,559,808 shares of the company’s stock valued at $263,704,000 after buying an additional 6,542,394 shares during the period. Wellington Management Group LLP boosted its stake in shares of Ionis Pharmaceuticals by 56.1% in the first quarter. Wellington Management Group LLP now owns 9,360,553 shares of the company’s stock valued at $376,295,000 after buying an additional 3,364,621 shares during the period. State Street Corp boosted its stake in shares of Ionis Pharmaceuticals by 20.5% in the first quarter. State Street Corp now owns 3,340,471 shares of the company’s stock valued at $134,285,000 after buying an additional 567,792 shares during the period. BB Biotech AG boosted its stake in shares of Ionis Pharmaceuticals by 7.9% in the first quarter. BB Biotech AG now owns 7,461,295 shares of the company’s stock valued at $299,944,000 after buying an additional 548,123 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Ionis Pharmaceuticals by 4.3% in the first quarter. Vanguard Group Inc. now owns 9,437,796 shares of the company’s stock valued at $379,399,000 after buying an additional 384,830 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by BNB Daily and is owned by of BNB Daily. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.baseball-news-blog.com/2017/08/19/ionis-pharmaceuticals-inc-nasdaqions-given-average-recommendation-of-hold-by-brokerages-updated-updated-updated.html.

Ionis Pharmaceuticals (NASDAQ:IONS) opened at 45.56 on Monday. Ionis Pharmaceuticals has a 1-year low of $24.58 and a 1-year high of $60.01. The stock’s 50 day moving average price is $52.74 and its 200 day moving average price is $46.90. The firm has a market cap of $5.65 billion, a P/E ratio of 219.04 and a beta of 3.14.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.03. The business had revenue of $104.15 million for the quarter, compared to the consensus estimate of $93.29 million. Ionis Pharmaceuticals had a return on equity of 17.34% and a net margin of 5.25%. The business’s revenue was up 170.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.47) earnings per share. Equities research analysts predict that Ionis Pharmaceuticals will post ($0.02) EPS for the current year.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply